Evidence map›Paper›PMID 28179474›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2017

Individual Differences in the Relative Reinforcing Effects of 3,4-Methylenedioxypyrovalerone under Fixed and Progressive Ratio Schedules of Reinforcement in Rats.

Brenda M Gannon, Kayla I Galindo, Kenner C Rice, Gregory T Collins

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Brenda M GannonDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas (B.M.G., K.I.G., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (G.T.C.); and Chemical Biology Research Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (K.C.R.).
Kayla I GalindoDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas (B.M.G., K.I.G., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (G.T.C.); and Chemical Biology Research Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (K.C.R.).
Kenner C RiceDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas (B.M.G., K.I.G., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (G.T.C.); and Chemical Biology Research Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (K.C.R.).
Gregory T CollinsDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas (B.M.G., K.I.G., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (G.T.C.); and Chemical Biology Research Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland (K.C.R.) CollinsG@uthscsa.edu.
National Institute on Alcohol Abuse and Alcoholism · USSouth Texas Veterans Health Care System · US

Funding

Training in Drug Abuse Research: Behavior and NeurobiologyT32DA031115 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHARLES P FRANCE · 2011 to 2026
$5.2M
Medicinal Chemistry of Drugs Acting on Biogenic Amine ReceptorsZIADA000532 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2020
$4.5M
Bath Salts: Abuse-related and Toxic EffectsR01DA039146 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Gregory Collins · 2015 to 2026
$4.0M
NIDA NIH HHS R01 DA039146NIDA NIH HHS T32 DA031115
6 · The paper itself

Abstract

The recreational use of designer drugs, including synthetic cathinones (bath salts), is associated with high levels of abuse and toxicity, and represents a growing threat to public health. 3,4-Methylenedioxypyrovalerone (MDPV) is a cocaine-like monoamine uptake inhibitor, and one of the most widely available and abused synthetic cathinones. The present study used male Sprague-Dawley rats to directly compare: (1) the acquisition of responding for MDPV and cocaine under a fixed ratio (FR) 1 schedule of reinforcement; (2) full dose-response curves for MDPV and cocaine under a FR5 schedule; and (3) progressive ratio (PR) schedules of reinforcement. Self-administration of MDPV and cocaine was acquired at comparable rates, and by a similar percentage of rats. Compared with cocaine, MDPV was ∼10-fold more potent and ∼3-fold more effective at maintaining responding (PR; final ratio completed). Unlike cocaine, for which little variability was observed among rats, the FR5 dose-response curve for MDPV was shifted ∼3-fold upward for a subset of rats (high-responders) relative to other rats with identical histories (low-responders). Compared with low-responding rats, high responders also self-administered more cocaine under the FR5 schedule, and earned significantly more MDPV, cocaine, and methamphetamine under a PR schedule of reinforcement. In addition to functioning as a significantly more effective reinforcer than either cocaine or methamphetamine, MDPV also appears to be unique in its capacity to establish an enduring phenotype in rats, characterized by unusually high levels of drug intake. Although the factors underlying this high-responder phenotype are unclear, they might be related to individual differences in human drug-taking behavior.

Indexed as

IndividualityReinforcement ScheduleAnimalsBenzodioxolesDesigner DrugsDose-Response Relationship, DrugMalePhotic StimulationPsychotropic DrugsPyrrolidinesRatsRats, Sprague-DawleyReinforcement, PsychologySelf AdministrationSynthetic CathinoneBenzodioxolesDesigner DrugsPsychotropic DrugsPyrrolidinesSynthetic Cathinone

Identifiers

PMID28179474
PMCPMC5363773
OpenAlexW2586347935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.